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Imre Fejes); Tartu (Margus Punab, Paul Korrovitz); TurThe aim of this study was to determine the association of hormone levels with the occurrence of muscu-
loskeletal pain. Men ages 40 to 79 years were recruited from population registers in 8 European centres.
Subjects were asked to complete a postal questionnaire, which enquired about lifestyle and the occur-
rence of musculoskeletal pain over the past month. Total testosterone (T), oestradiol (E2), luteinising hor-
mone (LH), and follicle-stimulating hormone (FSH) were assayed from a fasting blood sample. The
association between pain status and hormone levels was assessed using multinomial logistic regression
with results expressed as relative risk ratios (RRR) and 95% conﬁdence intervals (CI). A total of 3206 men
had complete data on pain status. Of these, 8.7% reported chronic widespread pain (CWP), whereas 50%
had some pain although not CWP and were classiﬁed as having some pain. T and E2 were not associated
with musculoskeletal pain, whereas signiﬁcant differences in LH and FSH levels were found between pain
groups. After adjustment for age and other possible confounders, the association between pain status and
both LH and FSH persisted. Compared with those in the lowest tertile of LH, those in the highest tertile
were more likely to report some pain (vs no pain, RRR = 1.28; 95% CI 1.09 to 1.50) and also CWP (vs no
pain, RRR = 1.51; 95% CI 1.10 to 2.07). Similar results were found for FSH. Gonadotrophins, but not sex
steroid hormone levels, are associated with musculoskeletal pain in men.
 2011 International Association for the Study of Pain. Published by Elsevier B.V.tudy of Pain. Published by Elsevier
: +44 161 2755043.
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Fibromyalgia, a noninﬂammatory rheumatic disorder character-
ised by chronic widespread pain (CWP), is one of the most common
reasons for consultation at rheumatology clinics inWestern Europe
and North America [29]. Extensive investigations over the past
20 years have begun to uncover the aetiology and biological pro-
cesses involved in the development of these symptoms.
A number of studies have explored the relationship between
musculoskeletal pain and various biomarkers in an attempt to ex-
plain the pathophysiological processes underlying pain develop-
ment. For example, a relationship has been reported between the
onset of CWP and altered functioning of the hypothalamic–
pituitary–adrenal axis [18]. Other studies [4,19] have explored
the relationship between the growth hormone insulin-like growth
factor 1 (IGF-1) axes and pain. Recent reports have also shown that
CWP is associated with low levels of vitamin D [9,17,23].
The role of reproductivehormones is less clearlydeﬁned.A recent
review outlined the potential role of sex hormones in relation to the
occurrence of musculoskeletal pain amongmen andwomen [5] and
highlighted that ﬁbromyalgia most often develops during the men-
opausal transition. Such observations have led to suggestions that
declines in female sex hormones, mainly oestrogens, may be linked
to the occurrence of pain amongwomen. Similarities also have been
drawn in men in terms of testosterone (T) having a putative protec-
tive role against the development of musculoskeletal pain [5].
Experiments in animal models have explored the relationship
between T and pain threshold [22], suggesting that low T could
be associated with decreased pain thresholds and increased pain
sensitivity. However, these relationships remain controversial in
humans, and the mechanisms by which T and other reproductive
hormones affect pain threshold and sensitivity remain unknown.
Few studies have looked speciﬁcally at the role of reproductive
hormones on the occurrence and severity of musculoskeletal pain.
Further, most data derive from women [15], reﬂecting their higher
prevalence of CWP and the distinct hormonal changes associated
with the menopause. It has also been suggested that the process
of pubertal development may initiate biological changes that pre-
dispose women in particular to experience symptoms, including
pain [13].
No current data exist looking at the association between the
occurrence of musculoskeletal pain and levels of sex steroid hor-
mones, gonadotrophins, and hypogonadism in men. Hypogonad-
ism, or androgen deﬁciency, adversely impacts functioning of
multiple organ systems [28]. Patients with classical hypogonadism
are routinely classiﬁed into those with secondary hypogonadism
(hypothalamic–pituitary failure) with low T and low or normal
gonadotrophins, or primary hypogonadism (testicular failure)
characterised by low T and elevated gonadotrophins. In addition,
men with normal T but elevated gonadotrophins form a distinct
subgroup, which may be characterised as subclinical hypogonad-
ism [26]. The relationship between these hypogonadal states and
musculoskeletal pain is not known.
The European Male Aging Study is a population-based study of
aging in middle-aged and older men [12]. We used data from this
study to explore the association between sex steroid hormones,
luteinising hormone (LH), and follicle-stimulating hormone (FSH),
and the occurrence of musculoskeletal pain.
2. Methods
2.1. Subjects
A total of 3369 men aged 40 to 79 years were recruited for par-
ticipation in the European Male Aging Study (EMAS) from popula-
tion registers in 8 European centres: Manchester (UK), Leuven(Belgium), Malmö (Sweden), Tartu (Estonia), Lodz (Poland), Szeged
(Hungary), Florence (Italy), and Santiago de Compostela (Spain). All
subjects were invited to participate by letter of invitation, which
included a short questionnaire (postal questionnaire). Those who
agreed to take part attended a local clinic/facility for detailed
assessments including an interviewer-assisted questionnaire,
height, weight and physical function measurements and fasting
blood sampling. Ethical approval for the study was obtained in
accordance with local institutional requirements in each centre,
and written informed consent was obtained from all participants.
2.2. Assessments
The postal questionnaire included questions about smoking and
the frequency of alcohol consumption (days per week). There were
also questions about the occurrence of pain (see below) and self-
reported comorbid conditions: hypertension, bronchitis, asthma,
peptic ulcer, epilepsy, diabetes mellitus, cancers, and cardiac, liver,
kidney, prostate, and thyroid disorders. A more detailed assess-
ment, undertaken when the patient subsequently attended the
clinic, included the Beck Depression Inventory to measure the
presence and severity of depression using a 21-item scale with
each item scored between 0 and 3 with a total score between 0
and 63 [3]. Higher scores indicate more depressive symptoms.
Physical performance was assessed using the Reuben’s Physical
Performance Test (PPT) [24], a direct observational instrument that
assesses multiple dimensions of physical function, as well as the
50-foot walk test (PPT walk), which requires subjects, on the com-
mand ‘‘go,’’ to walk 50 feet. The time taken to complete the task
was recorded. Higher scores indicate slower walking as a proxy
for lower extremity physical performance.
2.3. Assessment of pain status
CWP was classiﬁed using the deﬁnition in the American College
of Rheumatology criteria for ﬁbromyalgia [30]. These criteria re-
quire pain, lasting at least 3 months, distributed above and below
the waist, on the right and left sides of the body and in the axial
skeleton. All subjects who reported pain that did not satisfy these
criteria were classiﬁed as having other pain. This instrument has
been frequently used in population surveys, and its construct
validity has been demonstrated [10,16]. All subjects were asked,
‘‘In the past month, have you had any pain which has lasted for
one day or more?’’ Subjects who responded negatively were classi-
ﬁed as having no pain. If subjects answered positively, they were
asked to indicate the site(s) of pain on a body manikin with views
of the front, back, and both sides. To assess for chronicity of pain,
subjects were asked whether they had been aware of the pain for
3 months or more.
2.4. Sex steroid and gonadotropin hormone assessment
A single fasting venous blood sample was obtained before 10:00
am. Measurements of total T and oestradiol (E2) were carried out
by gas chromatography–mass spectrometry [11]. Dehydroepian-
drosterone sulphate, sex hormone binding globulin (SHBG), LH,
and FSH were assayed by the Modular E170 platform electrochem-
iluminescence immunoassay (Roche Diagnostics, Mannheim,
Germany) as described elsewhere [32]. Free T and E2 levels were
derived from total hormone, SHBG, and albumin concentrations
[27].
2.5. Statistical analysis
Body mass index (BMI) was calculated as body weight (kg)
divided by the square of height (m2). Frequency of alcohol
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quent (1 to 4 days per week) and frequent (P5 days per week).
Analysis of variance or Kruskall–Wallis (for nonnormal continuous
variables) tests were used to determine whether there were differ-
ences in the pain groups (CWP/some pain/no pain) for hormone
levels and other continuous variables; v2 tests were used for cate-
gorical variables. Multinomial logistic regression was used to as-
sess the relationship between pain status (dependent variable)
and the various sex steroid and gonadotrophin hormones. In these
analyses, hormone levels were initially included as continuous
variables. Subjects were also categorised into tertiles based on
the pain status distribution of individual sex steroid and gonado-
trophin levels (with the lowest or highest tertile as referent). This
categorical approach allowed for an examination of any potential
nonlinear relationships between hormone levels and musculoskel-
etal pain. Analyses were performed after adjustment for age and
after subsequent adjustment for a range of possible confounders
including smoking, alcohol intake, BMI, self-reported morbidity
(one or more vs none), PPT walk time, Beck Depression Inventory,
and centre. In the multinomial logistic regression analyses, the cat-
egory outcome of no pain was used as the base comparison group.
We also explored whether there was any combined effect of LH
and FSH on pain status. Gonadotrophin status was constructed as a
4-group variable using LH and FSH tertiles. The 4 groups were:
high gonadotrophin (highest tertiles of both LH and FSH), nor-
mal/low gonadotrophin (both LH and FSH below their respective
highest tertile levels), and 2 discordant groups (high LH and nor-
mal/low FSH) and (normal/low LH and high FSH). The association
between these 4 gonadotrophin groups and pain status was ex-
plored in the same fashion as above.
Additional analyses were carried out using a 4-category variable
of functional gonadal status (eugonadal, primary, secondary, and
compensated hypogonadism) constructed using 2 thresholds as
described previously [26], ie, a T level of 10.5 nmol/L, this T cut
point of 10.5 nmol/L corresponded to the median value of the T
thresholds recently published by our group [31], whereas the LH
threshold of 9.4 U/L corresponds to the 97.5th percentile (theTable 1
Subject characteristics: all subjects, and by pain status.
Analysis sample N = 3206 No pain
Age at baseline (years) 59.86 (11.03) 59.84 (
Height (m) 173.64 (7.35) 173.61
Weight (kg) 83.48 (13.96) 82.18 (
Body mass index (kg/m2) 27.67 (4.10) 27.25 (
Total testosterone (nmol/L) 16.49 (6.03) 16.65 (
Free testosterone (pmol/L) 290.59 (88.77) 292.56
Median interquartile range)
Slow walking speed (seconds) 13.17 (3.00) 12.93 (
Beck depression inventory 5.00 (8.00) 4.00 (7
LH (U/L) 5.23 (3.38) 5.03 (3
FSH (U/L) 6.04 (5.32) 5.86 (5
DHEAS (lmol/L) 4.00 (3.60) 4.00 (3
SHBG (nmol/L) 39.10 (22.90) 39.85 (
E2 (pmol/L) 70.08 (30.51) 69.97 (
Free E2 (pmol/L) 1.20 (0.52) 1.19 (0
Count (%)
Drugs related to hypogonadism 139 (4.34) 53 (4.0
Number of comorbidities (1 or more) 1634 (51.71) 587 (45
Smoking status (current) 667 (20.96) 251 (19
Alcohol intake (P5 days/week) 739 (23.17) 305 (23
Morbidities included heart conditions, high blood pressure, stroke, cancer, bronchitis, as
⁄P value for (continuous variables): ANOVA or Kruskall–Wallis test. ⁄P value for categor
LH = luteinising hormone, FSH = follicle-stimulating hormone, SHBG = sex hormon
SD = standard deviation.upper limit of normal) value in the youngest group (40 to 44
years) in our analysis cohort. The 4 categories were: eugonadal
(TP 10.5 nmol/L and LH 6 9.4 U/L), secondary hypogonadism (T <
10.5 nmol/L and LH 6 9.4 U/L), primary hypogonadism (T < 10.5
nmol/L and LH > 9.4 U/L), and compensated hypogonadism
(TP 10.5 nmol/L and LH > 9.4). Similar groups were also created
using the 97.5th percentile of FSH from the youngest age group
(age 40 to 44 years), this FSH level was 15.11 U/L. The relationships
between gonadal status (independent variable) and pain status
(outcome) was assessed using the same modeling strategy as
above.
Robust standard errors were considered to take into account the
hierarchy of the study design (individuals nested within centres).
Results are expressed as relative risk ratios (RRR) with 95% conﬁ-
dence intervals (CI) for the multinomial logistic regression models.
All statistical analyses were conducted using Intercooled STATA
version 9.2.
3. Results
3.1. Subject characteristics
Of the 3369 participants, 3206 (95%) provided full data on pain
status and were available for the current analysis. Of these 1314
(41%) reported no pain in the past month, 278 (9%) reported pain
that satisﬁed the American College of Rheumatology (ACM)
criteria for CWP, whereas 1614 (50%) were classiﬁed as having
other pain, ie, men who had some pain although not CWP. The
baseline characteristics of the analysis sample are shown in
Table 1. The mean (SD) age was 59.9 (11.0) years, and mean
(SD) BMI was 27.7 (4.1) kg/m2. Just over one ﬁfth were current
smokers, and a similar proportion (23%) consumed alcohol on 5
or more days per week. Over 50% of the men reported 1 or more
morbid conditions. Pain status was independent of any medica-
tions likely to affect hypothalamic–pituitary–testicular function
(anabolic-androgenic steroids, Dehydroepiandrosteron (DHEA),
anti-androgens, gonadotrophin-releasing hormone agonists, and1314 (41%) Some pain 1614 (50%) CWP 278 (9%) P value⁄
Mean (SD)
10.89) 59.87 (11.16) 59.84 (10.94) .99
(7.40) 173.71 (7.36) 173.33 (7.14) .72
12.92) 84.08 (14.26) 86.14 (16.28) <.001
3.84) 27.85 (4.20) 28.59 (4.46) <.001
6.02) 16.34 (6.03) 16.57 (6.12) .36
(88.92) 290.11 (88.77) 284.00 (88.04) .33
2.80) 13.20 (3.03) 13.80 (3.14) <.001
.00) 6.00 (7.00) 8.00 (11.00) <.001
.05) 5.32 (3.53) 5.77 (3.84) .001
.00) 6.14 (5.37) 6.71 (5.48) .003
.70) 4.00 (3.65) 4.10 (3.30) .57
22.50) 38.20 (22.90) 40.60 (24.20) .04
27.97) 70.19 (32.16) 70.04 (33.11) .64
.51) 1.21 (0.54) 1.19 (0.53) .61
3) 68 (4.21) 18 (6.47) .18
.26) 876 (55.16) 171 (62.18) <.001
.25) 344 (21.49) 72 (25.99) <.03
.34) 396 (24.67) 38 (13.72) <.001
thma, peptic ulcer, epilepsy, diabetes, and liver, kidney, and prostate diseases.
ical variables v2 test of independence.
e-binding globulin, DHEAS = dehydroepiandrosterone sulphate, E2 = oestradiol,
Table 2
Multinomial logistic regression models testing associations between hormones (continuous and tertiles) and musculoskeletal pain.
RRR (95% CI)
Model I Model II
Some pain CWP Some pain CWP
Total T (nmol/L)
Continuous 0.99 (0.98 to 1.00) 1.00 (0.98 to 1.02) 1.00 (0.99 to 1.01) 1.01 (0.99 to 1.04)
Tertiles Highest Referent Referent Referent Referent
Middle 1.03 (0.86 to 1.24) 1.17 (0.85 to 1.60) 0.99 (0.86 to 1.14) 1.12 (0.64 to 1.96)
Lowest 1.19 (0.99 to 1.42) 1.14 (0.82 to 1.58) 1.02 (0.86 to 1.21) 0.88 (0.59 to 1.31)
Free T (pmol/L)
Continuous 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.00)
Tertiles Highest Referent Referent Referent Referent
Middle 1.08 (0.90 to 1.30) 1.15 (0.82 to 1.59) 1.04 (0.86 to 1.26) 1.04 (0.75 to 1.44)
Lowest 1.07 (0.89 to 1.30) 1.28 (0.91 to 1.79) 0.89 (0.64 to 1.23) 0.92 (0.63 to 1.34)
LH (U/L)
Continuous 1.03 (1.01 to 1.05)** 1.03 (1.00 to 1.06) 1.03 (1.00 to 1.05)* 1.02 (0.99 to 1.05)
Tertiles Highest Referent Referent Referent Referent
Middle 1.04 (0.87 to 1.24) 0.91 (0.65 to 1.27) 1.07 (0.87 to 1.31) 0.92 (0.57 to 1.50)
Lowest 1.29 (1.07 to 1.55)** 1.66 (1.21 to 2.29)** 1.28 (1.09 to 1.50)** 1.51 (1.10 to 2.07)*
FSH (U/L)
Continuous 1.01 (1.00 to 1.02)** 1.01 (1.00 to 1.03) 1.01 (1.00 to 1.02) 1.01 (1.00 to 1.02)
Tertiles Highest Referent Referent Referent Referent
Middle 1.17 (0.97 to 1.40) 1.25 (0.90 to 1.75) 1.13 (0.84 to 1.52) 1.14 (0.77 to 1.69)
Lowest 1.25 (1.03 to 1.51)* 1.69 (1.21 to 2.37)** 1.23 (0.99 to 1.52) 1.47 (1.15 to 1.87)**
DHEAS (lmol/L)
Continuous 0.99 (0.96 to 1.02) 0.99 (0.94 to 1.05) 0.99 (0.96 to 1.02) 1.01 (0.97 to 1.05)
Tertiles Highest Referent Referent Referent Referent
Middle 1.06 (0.87 to 1.27) 1.04 (0.75 to 1.45) 1.09 (0.87 to 1.36) 1.00 (0.73 to 1.35)
Lowest 1.12 (0.91 to 1.38) 0.97 (0.67 to 1.41) 1.13 (0.88 to 1.44) 0.81 (0.59 to 1.11)
SHBG (nmol/L)
Continuous 1.00 (0.99 to 1.00) 1.00 (1.00 to 1.01) 1.00 (0.99 to 1.00) 1.00 (1.00 to 1.01)
Tertiles Highest Referent Referent Referent Referent
Middle 0.80 (0.67 to 0.96)* 1.09 (0.79 to 1.52) 0.87 (0.73 to 1.03) 1.32 (0.87 to 2.01)
Lowest 0.85 (0.70 to 1.03) 1.20 (0.85 to 1.70) 0.93 (0.70 to 1.23) 1.32 (0.88 to 1.98)
E2 (pmol/L)
Continuous 1.00 (1.00 to 1.00) 1.00 (1.00 to 1.01) 1.00 (1.00 to 1.01) 1.00 (0.99 to 1.01)
Tertiles Highest Referent Referent Referent Referent
Middle 0.87 (0.73 to 1.04) 0.81 (0.58 to 1.12) 0.87 (0.69 to 1.10) 0.79 (0.54 to 1.17)
Lowest 1.05 (0.88 to 1.26) 1.17 (0.86 to 1.61) 0.99 (0.76 to 1.28) 1.04 (0.71 to 1.51)
Free E2 (pmol/L)
Continuous 1.12 (0.95 to 1.32) 1.00 (0.74 to 1.36) 1.03 (0.77 to 1.38) 0.91 (0.63 to 1.31)
Tertiles Highest Referent Referent Referent Referent
Middle 1.03 (0.86 to 1.24) 0.90 (0.65 to 1.25) 1.06 (0.88 to 1.28) 0.91 (0.57 to 1.45)
Lowest 1.04 (0.87 to 1.25) 1.08 (0.79 to 1.48) 0.99 (0.73 to 1.33) 1.00 (0.59 to 1.69)
Model (I) adjusted for age. Model (II) adjusted for age, smoking status, alcohol intake, body mass index, morbidities, Reuben’s Physical Performance Test walk time,
depression, and centre.
Separate model for each hormone. Base category for the outcome was no pain. For hormones as continuous variables, RRRs correspond to a 1-unit increases in the relevant
hormone.
RRR = relative risk ratios, CI = conﬁdence interval, LH = luteinising hormone, FSH = follicle-stimulating hormone, SHBG = sex hormone-binding globulin, DHEAS = dehydro-
epiandrosterone sulphate, E2 = oestradiol, CWP = chronic widespread pain.
* P < .05.
** P < .01.
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sants) (Table 1).
3.2. Relationship between pain status and hormone variables
Hormonal distributions by pain status are shown in Table 1. Sig-
niﬁcant differences between levels of gonadotrophins by pain
group were observed (P < .01, Kruskall–Wallis test) for both LH
and FSH. There were no signiﬁcant differences between pain
groups in total and free T levels.
Table 2 shows data concerning the association between pain
status and sex steroid, and gonadotrophin levels. Model I shows
the age-adjusted RRRs, and model II the RRRs in the fully adjusted
model.In model II, high LH levels were associated with the presence of
musculoskeletal pain: the RRRs may be interpreted as ‘‘the risk of
being in the some pain group versus being in the no pain group
was 1.28 (95% CI 1.09 to 1.50) times as great for men in the highest
LH tertile as in those in the lowest LH tertile.’’ The risk of being in
the CWP group versus being in the no pain group was 1.51 (95% CI
1.10 to 2.07) times as great for men in the highest LH tertile as for
those in the lowest LH tertile (Table 2). Looking at the gonadotro-
phins (LH and FSH) as continuous variables, there was an associa-
tion mainly with some pain, although with CWP the relationships
were at the borderline of statistical signiﬁcance, possibly due to a
lack of statistical power (Table 2).
Similarly, those in the highest tertile of FSH were more likely to
report CWP (vs no pain, RRR = 1.47; 95% CI 1.15 to 1.87) (model II,
Table 3
Multinomial logistic regression models testing joint association between high, normal/low FSH and LH levels and musculoskeletal pain.
RRR (95% CI)
Model I Model II
Some pain CWP Some pain CWP
Combination of LH and FSH levels
Normal/low LH and normal/low FSH
n = 1788 (56.14%) Referent Referent Referent Referent
Normal/low LH and high FSH n = 342 (10.74%) 0.95 (0.74 to 1.22) 1.13 (0.72 to 1.76) 0.99 (0.86 to 1.15) 1.06 (0.76 to 1.47)
High LH and normal/low FSH n = 338 (10.61%) 1.16 (0.90 to 1.48) 1.53 (1.01 to 2.43)* 1.14 (0.87 to 1.49) 1.39 (0.85 to 2.30)
High LH and high FSH n = 717 (22.51%) 1.31 (1.07 to 1.59)** 1.93 (1.39 to 2.69)*** 1.29 (1.06 to 1.56)* 1.69 (1.36 to 2.10)***
Low corresponds to LH/FSH levels below the highest tertiles, high means in the highest tertiles.
Model I: adjusted for age. Model II: adjusted for age, smoking status, alcohol intake, body mass index, morbidities, Reuben’s Physical Performance Test walk time, depression,
and centre. Base category for the outcome is no pain.
RRR = relative risk ratios, CI = conﬁdence interval, LH = luteinising hormone, FSH = follicle-stimulating hormone, CWP = chronic widespread pain.
* P < .05.
** P < .01.
*** P < .001.
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status and reproductive hormones (SHBG) in the ﬁnal models
(model II).
Table 3 shows the joint effect of LH and FSH on reporting pain.
In total, 10.7% of subjects had normal/low LH and high FSH, 10.6%
had high LH and normal/low FSH, 22.5% had high LH and high
FSH, and the remaining 56.1% had normal/low LH and normal/
low FSH.
In the fully adjusted models, only men in the high LH and FSH
group were more likely to report some pain (vs no pain) (RRR =
1.29; 95% CI 1.06 to 1.56), and (vs. no pain) CWP (RRR = 1.69; 95%
CI 1.36 to 2.10). No associations were observed in the other groups.
3.3. Pain status and gonadal status
As outlined above, men were categorised into 1 of 4 groups
based on their level of total T and gonadotrophin hormone (either
LH or FSH). Compared with those in the eugonadal group, those in
the compensated group were more likely to report some pain (vs
no pain) (RRR = 1.71; 95% CI 1.36 to 2.15) and also CWP (vs. no
pain) (RRR = 1.95; 95% CI 1.39 to 2.73) (Fig. 1A). A weak negative
association was found with primary hypogonadism (Fig. 1A).
Broadly similar ﬁndings were observed when the 4 groups were
deﬁned on the basis of their FSH, rather than LH, level (Fig. 1B).
Additionally, we repeated the same analyses after excluding 14
men who reported opioid use (10 of these 14 men were classiﬁed
as some pain and the remaining 4 reported CWP), the results were
similar to those presented here (data not shown).
4. Discussion
We report here the ﬁndings of the ﬁrst population-based study
on the associations between male reproductive hormones and
musculoskeletal pain. We found signiﬁcant associations between
higher levels of gonadotrophins and musculoskeletal pain after
adjustment for potential health and lifestyle confounders. There
was, however, no association between musculoskeletal pain and
sex steroid levels.
Studies in women [1,6,7,15,21] provide somewhat conﬂicting
data concerning the relationship between reproductive hormone
levels and musculoskeletal pain. In a population-based study [15]
exploring the relationship between hormones and CWP in women,
no clear associations were observed. Results from another case
control study [21] suggested that ﬁbromyalgia was unlikely to be
attributed to any signiﬁcant hormonal disruptions. In contrast to
these observations, however, higher gonadotrophin levels werereported among ﬁbromyalgia patients compared with healthy con-
trols [7]. Our data, based on the occurrence of musculoskeletal
pain, support these ﬁndings and extend them to men.
A study [8] involving 57 women followed up during their men-
opausal transition found an association between musculoskeletal
pain and E2. In EMAS, we found no relationship between E2 and
pain status among middle-aged and older men. A possible explana-
tion for the discrepancy is that higher levels of oestrogens in wo-
men may predispose them to greater pain than men [5].
What are the possible mechanism underlying our observa-
tions? The absence of any association between androgens and
pain status observed in this cohort may suggest that the age-
related decline of T in men may not have an important role in
the occurrence of pain, in contrast with the strong association
between changes in oestrogen levels and musculoskeletal pain
in women. However, disruptions in testicular function (elevated
gonadotrophins) appear to be related to the presence of muscu-
loskeletal pain. It is possible that high gonadotrophin levels
among men with CWP may be considered as a biomarker for a
previous T decline within the normal physiological range (10
to 30 nmol/L), thus indicating a readjustment of the pituitary–
testicular feedback set point that compensates for defective T
feedback at the hypothalamic–pituitary level [14], or as genuine
androgen deﬁciency with respect to the man’s individual normal
level. If so, it might be expected that there would be an associ-
ation with T that was not the case here. Alternatively, the onset
of CWP as a marker of poor health could result in an increase in
gonadotrophin levels as an early sign of imminent testicular fail-
ure. A further possibility is that alterations in the hormonal feed-
back mechanisms controlled by the hypothalamus may play a
role in the symptomatology of ﬁbromyalgia [20]. Interestingly,
the LH receptor has been localised not only in the reproductive
organs but also as a functional protein within the central ner-
vous system, including regions of the brain involved in sensory
functions [2]. It is biologically plausible, therefore, that LH may
have either direct effects within the central nervous system or
indirect effects via regulation of neurosteroid production [2],
although this would not explain the observed association of
FSH with pain status. However, these 2 hormones are jointly
regulated by the hypothalamic gonadotrophin-releasing hormone
and their levels usually change in parallel. Prospective data are
warranted to conﬁrm these ﬁndings and to help determine the
temporal nature of the relationships.
Our study has a number of strengths: it was a large population-
based study that used standardised, well-validated instruments to
assess pain and putative confounders. The study also used the
0.3
0.8
1.3
1.8
2.3
2.8
R
R
R
 (9
5%
 C
I)
Compensated 
hypogonadism
Primary
hypogonadism
Secondary 
hypogonadism
Some pain
CWP
1.0
***
***
*
R
R
R
 (9
5%
 C
I)
R
R
R
 (9
5%
 C
I)
R
R
R
 (9
5%
 C
I)
0.3
0.8
1.3
1.8
2.3
2.8
R
R
R
 (9
5%
 C
I)
Compensated 
hypogonadism
Primary
hypogonadism
Secondary 
hypogonadism
Some pain
CWP
1.0
*
R
R
R
 (9
5%
 C
I)
**
R
R
R
 (9
5%
 C
I)
R
R
R
 (9
5%
 C
I)
A
B
Fig. 1. Results of multinomial logistic regression exploring the association between hypogonadal status and musculoskeletal pain. (A) Combination of total T and LH. (B)
Combination of total T and FSH. Multinomial logistic regression models: adjusted for age, smoking status, alcohol intake, body mass index, morbidities, Physical Performance
Test walk time, depression, and centre. The base category for the outcome is no pain. The RRR indicates the likelihood of being classiﬁed in one of the outcome categories,
some pain or CWP compared with the base category no pain. They may be interpreted by saying, for example, the risk of being in the some pain group versus being in the no
pain group was 1.95 (P < .001) times greater for men in the compensated hypogonadism group as for eugonadal men (A). CI = conﬁdence interval; CWP = chronic widespread
pain; LH = luteinising hormone; FSH = follicle-stimulating hormone; RRR = relative risk ratios; T = testosterone. ⁄P < .05, ⁄⁄P < .01, ⁄⁄⁄P < .001.
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152 (2011) 1495–1501state-of-the-art mass spectrometry-based method (gas chroma-
tography–mass spectrometry) for measuring serum T levels, as
recommended recently by the Endocrine Society’s Positional State-
ment [25]. There are, however, some methodological limitations
that need to be considered in interpreting the ﬁndings. It is possi-
ble that the prevalence of pain among those who participated may
have differed from that in those who declined to participate, and
some caution is needed in interpreting the data. Factors inﬂuenc-
ing participation are, however, unlikely to have inﬂuenced the re-
sults of the risk factor analysis, which was based on an internal
comparison of those who participated. Given the cross-sectional
nature of the study data, it is not possible to determine the tempo-
ral nature of the relationship between pain and reproductive hor-
mone status for which future prospective data of the EMAS cohortare needed. Finally, our results were derived from a population
sample of middle-aged and older European men, and should be
extrapolated beyond this group with caution.
In summary, gonadotrophins, but not sex steroid hormone
levels, are associated with musculoskeletal pain in men. Further
prospective data are required to conﬁrm these ﬁndings and to
determine the temporal nature of the observed associations.Ethics approval
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